Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Tuesday 10 July 2018, from 10am to 1pm

Venue: 10 Spring Gardens
London
SW1A 2BU

Present:
1. Dr Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice Chair) Present for all notes
3. Mr Mark Chapman Present for all notes
4. Professor John Cairns Present for all notes
5. Mr Diar Fattah Present for all notes
6. Ms Susan Faulds Present for all notes
7. Dr Mark Glover Present for all notes
8. Mr Richard Hoddes Present for all notes
9. Dr Mona Johnson Present for all notes
10. Dr Sanjay Kinra Present for all notes
11. Dr Nicholas Latimer Present for all notes
12. Mr Christopher O'Regan Present for notes 1 to 16
13. Dr Stephen Smith Present for all notes
14. Mr William Turner Present for all notes
15. Mr Nigel Westwood Present for all notes
16. Professor Sarah Wild Present for all notes

In attendance:

Mirella Marlow
Programme Director, National Institute for Health and Care Excellence
Present for all notes

Dr Melinda Goodall
Associate Director, National Institute for Health and Care Excellence
Present for all notes

Jeremy Powell
Project Manager, National Institute for Health and Care Excellence
Present for all notes

Sandra Aleknavice
Administrator, National Institute for Health and Care Excellence
Present for all notes

Jessica Cronshaw
Technical Analyst, National Institute for Health and Care
Present for notes 1 to 16
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of abiraterone for treating newly diagnosed metastatic hormone-naïve prostate cancer [ID945] and cabozantinib for untreated
metastatic renal cell carcinoma [ID1208].

2. The Chair informed the Committee of the non-public observers at this meeting: Aalya Al-Assaf, Helen Barnett, Chloe Kastoryano, Edgar Masanga, Rebecca Smittenaar and Dr Alice Turnbull.

3. Apologies were received from Professor Stephen Palmer, Professor Nicky Welton and Dr Stuart Williams.

Any other Business

4. The Committee were given an update on the progress of other appraisals previously seen by the Committee and an update on personnel changes within the NICE Technology Appraisals team.

Appraisal of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945]

Part 1 – Open session

5. The Chair welcomed the invited experts: Professor Peter Clark, Dr Miriam Brazzelli and Dr Ewen Cummins to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Janssen to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Amanda Adler, Dr Sanjeev Patel, Mr Mark Chapman, Professor John Cairns, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Mr Christopher O'Regan, Dr Stephen Smith, Mr William Turner, Mr Nigel Westwood and Professor Sarah Wild all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945].

7.2. Dr Nicholas Latimer declared that he had received a consultancy fee from Janssen for providing a half-day training course on survival analysis. He also declared that he had received a consultancy fee from Astra Zeneca for giving advice on survival modelling for durvalumab as a monotherapy among patients with stage IIIB–IV NSCLC.

7.2.1. It was agreed that as this declaration did not relate to the intervention product or to a specific comparator product Dr Latimer could participate in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone for
treating newly diagnosed metastatic hormone-naive prostate cancer [ID945].

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945].

10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

13. The Chair then thanked the company representatives and Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945].

15.1. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Notes from the last meeting

17. The minutes of the Committee meetings held on 10 May 2018 and 6 June 2018 were approved.

Appraisal of cabozantinib for untreated metastatic renal cell carcinoma [ID1208]

Part 1 – Open session
18. The Chair welcomed the invited experts: Professor Peter Clark, Professor Joanne Lord and Dr Jonathan Shepherd to the meeting and they introduced themselves to the Committee.

19. The Chair welcomed company representatives from Ipsen to the meeting.

20. The Chair asked all Committee members to declare any relevant interests

20.1. Dr Amanda Adler, Dr Sanjeev Patel, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Dr Stephen Smith, Mr William Turner, Mr Nigel Westwood and Professor Sarah Wild all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabozantinib for untreated metastatic renal cell carcinoma [ID1208].

20.2. Professor John Cairns declared before the meeting that he has received payment for participating in an MCDA workshop organised by the LSE and funded by Novartis. The focus was on the MCDA method and not on a specific Novartis product.

20.2.1. It was agreed that this declaration would not prevent Professor Cairns from participating in this section of the meeting.

20.3. Dr Nicholas Latimer declared that he had received consultancy fees from Pfizer relating to other disease areas and was a member of Pfizer’s global modelling committee between January 2017 and December 2017.

20.3.1. It was agreed that as this declaration did not relate to a specific comparator product Dr Latimer could participate in this section of the meeting.

21. The Chair asked all NICE Staff to declare any relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabozantinib for untreated metastatic renal cell carcinoma [ID1208].

22. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabozantinib for untreated metastatic renal cell carcinoma [ID1208].

23. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

25. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

26. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

27. Discussion on confidential information continued. This information was supplied by the company.

28. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

29. The Committee continued to discuss the clinical and cost effectiveness of cabozantinib for untreated metastatic renal cell carcinoma [ID1208].

29.1. The committee decision was based on consensus.

30. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

Thursday 2 August 2018 at 10 Spring Gardens, London SW1A 2BU.